Recro Pharma (NASDAQ: REPH) is a revenue-generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings. The company operates through two business divisions: an acute care, hospital product division and a revenue-generating contract development and manufacturing, or CDMO, division. The company’s lead product candidate is a proprietary injectable form of meloxicam, which is a long-acting preferential COX-2 inhibitor. Since injectable meloxicam is in the non-opioid drug class, Recro Pharma believes it will overcome many of the issues that are associated with commonly prescribed opioid therapeutics, such as respiratory depression, constipation, excessive nausea and vomiting. It also has no addictive potential and maintains meaningful analgesic effects for pain relief. For more information, visit the company’s website at www.recropharma.com.
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com